News Banner

Recent News

US House Committee 340B Hearing Video - March 31, 2015

If you are interested in viewing a recording of the March 24 hearing, the is available on the Energy and Commerce committee website.  (View Details)

HRSA Has Released Their Monthly Program Update for March - March 27, 2015

The Health Resources and Services Administration’s Office of Pharmacy Affairs (OPA) has released their monthly program update for March. This month, OPA updates 340B stakeholders on “Program Integrity: Best Practices for Hospital Registrations.” OPA has shared best practices based upon lessons learned during the new hospital registration process including verifying correct email of the government official and registering early, ensuring appropriate Authorizing Official (AO) listing, having your cost report available, submitting a separate registration for each service off-sit …  (View Details)

House Subcommittee Holding 340B Hearing - March 24, 2015

According to the committee’s news release, “subcommittee members will hear testimony from witnesses from the Health Resources and Services Administration (HRSA), Government Accountability Office, and the Department of Health and Human Services Office of Inspector General about the federal drug discount program.”  (View Details)

MedPAC to Discuss 340B Program - March 6, 2015

According to (CQ) (3/6, subscription publication), the March 5 snowstorm resulted in the House Energy and Commerce Committee’s health panel rescheduling its “hearing on the government’s 340B discount drug program, but Congress’ advisers on Medicare soldiered on with a separate discussion about the issue.” The Medicare Payment Advisory Commission (MedPAC) will include a discussion of the 340B program in its June report to Congress; however, Glenn M. Hackbarth, the Chairman of MedPAC, said, “We are not yet close to the point of making recommendations.” …  (View Details)

340B to be Discussed at Medicare Advisory Meeting - March 2, 2015

The Medicare Payment Advisory Commission (MedPAC) is an independent congressional agency that advises the U.S. Congress on issues affecting the Medicare program. The 17-member committee of appointed individuals meets publicly to discuss policy issues and determine recommendations to Congress. On Thursday, March 5th, 340B is on the agenda of a session titled “Part B drug payment policy issues.” The discussion will focus on how 340B entities are paid steep discounts, yet Medicare reimburses these entities at the same rate as non-340B entities. Please see the .  (View Details)

HRSA Has Released Their Monthly Program Update for February - February 24, 2015

The Health Resources and Services Administration’s Office of Pharmacy Affairs (OPA) has released their monthly program update for February. This month, OPA updates 340B stakeholders on “Program Integrity: Best Practices from Leading Practice Sites.” OPA has shared the best practices that leading practice sites from the 340B Peer-to-Peer Program employ to avoid the three major areas of non-compliance found in audits; eligibility, diversion, and duplicate discounts. Please take the time to read this important .  (View Details)

OPA Director Commander Pedley’s Address to 340B Winter Coalition Meeting - February 16, 2015

During February's 340B Winter Coalition meeting in San Francisco, Office of Pharmacy Affairs Director, Commander Krista Pedley addressed attendees on developments in 340B, advances in the program, and efforts taken to protect program integrity. Commander Pedley also encouraged stakeholders to take advantage of the vast amount of resources available to support 340B compliance including the 340B Peer to Peer program and education and compliance support provided by Apexus. We would like to encourage you to view the video .  (View Details)

2015 State of Apexus - February 10, 2015

During the 2015 340B Coalition Winter Meeting, Apexus President Christopher A. Hatwig gave a presentation on what to expect from 340B, HRSA, the Prime Vendor Program, and Apexus over the next year. The 2015 update touched on a number of topics important to 340B stakeholders. Hatwig explained that Apexus will focus on growing the contract portfolio, maintaining high customer satisfaction, advancing the manufacturer refund program, implementing specialty pharmacy solutions to support access, and expanding educational offerings focused on compliance and program integrity. Please take the time to …  (View Details)

View News Archive